Steven Kafka

Steven J.
Kafka currently works at DA32 Life Science Tech Acquisition Corp., as Chief Executive Officer, Glympse Bio, Inc., as Director, BigHat Biosciences, Inc., as Director, Rome Therapeutics, Inc., as Director from 2021, ImmuneID, Inc., as Director, Sunbird Bio, Inc., as Director, and Section 32 LLC, as General Partner from 2019.
Dr. Kafka also formerly worked at Thrive Earlier Detection Corp., as Executive Chairman & Co-Chief Executive Officer from 2019 to 2021, ArcherDX LLC, as Executive Chairman from 2019 to 2020, Millennium Pharmaceuticals, Inc., as Senior Director-Finance, Forrester Research, Inc., as Research Director, Relay Therapeutics, Inc., as Independent Director from 2018 to 2019, Aileron Therapeutics, Inc., as Chief Financial Officer, VP-Finance & Operations from 2009 to 2011, Infinity Pharmaceuticals, Inc., as Vice President-Finance, Strategic Decisions Group, as Senior Manager-Engagement, Third Rock Ventures LLC, as Partner from 2018 to 2019, and Foundation Medicine, Inc., as President & Chief Operating Officer from 2015 to 2018.
Dr. Kafka received his doctorate degree in 1996 from Harvard University and undergraduate degree in 1991 from Stanford University.